Cargando…
Checkpoint inhibitors in hematological malignancies
Inhibitory molecules such as PD-1, CTLA-4, LAG-3, or TIM-3 play a role to keep a balance in immune function. However, many cancers exploit such molecules to escape immune surveillance. Accumulating data support that their functions are dysregulated in lymphoid neoplasms, including plasma cell myelom...
Autores principales: | Ok, Chi Young, Young, Ken H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422942/ https://www.ncbi.nlm.nih.gov/pubmed/28482851 http://dx.doi.org/10.1186/s13045-017-0474-3 |
Ejemplares similares
-
Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021) -
Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020) -
Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
por: Fattizzo, Bruno, et al.
Publicado: (2022) -
Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023) -
Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)